Distinguishing adrenal cortical carcinomas and adenomas: A study of clinicopathological features and biomarkers

Histopathology

Volumn 64, Issue 4, 2014, Pages 567-576

  Wang, Cuiping ^a   Sun, Yang ^a   Wu, Huanwen ^a   Zhao, Dachun ^a   Chen, Jie ^a  

^a TSINGHUA UNIVERSITY   (China)

Author keywords

Adrenal cortical tumours; Clinicopathological features; Diagnosis; Differentiation; Hsa mir 483 3p; in situ hybridization

Indexed keywords

ADRENAL CORTICAL TUMOURS; CLINICOPATHOLOGICAL FEATURES; DIAGNOSIS; DIFFERENTIATION; HSA-MIR-483-3P; IN-SITU HYBRIDIZATION;

ADOLESCENT; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL ADENOMA; ADRENOCORTICAL CARCINOMA; ADULT; AGED; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INSULIN-LIKE GROWTH FACTOR II; MALE; MICRORNAS; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RNA, NEOPLASM; SMAD4 PROTEIN; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84895072281     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12283     Document Type: Article

References (38)

1. Grumbach MM, Biller BM, Braunstein GD et al. Management of the clinically inapparent adrenal mass ('incidentaloma'). Ann. Intern. Med. 2003; 138; 424-429.
2. Icard P, Goudet P, Charpenay C et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J. Surg. 2001; 25; 891-897.
3. Favia G, Lumachi F, Carraro P, D'Amico DF. Adrenocortical carcinoma. Our experience. Minerva Endocrinol. 1995; 20; 95-99.
4. Wajchenberg BL, Albergaria Pereira MA, Medonca BB et al. Adrenocortical carcinoma: clinical and laboratory observations. Cancer 2000; 88; 711-736.
5. Weiss LM. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am. J. Surg. Pathol. 1984; 8; 163-169.
6. Weiss LM, Medeiros LJ, Vickery AL Jr. Pathologic features of prognostic significance in adrenocortical carcinoma. Am. J. Surg. Pathol. 1989; 13; 202-206.
7. Aubert S, Wacrenier A, Leroy X et al. Weiss system revisited: a clinicopathological and immunohistochemical study of 49 adrenocortical tumors. Am. J. Surg. Pathol. 2002; 26; 1612-1619.
8. Gicquel C, Bertagna X, Gaston V et al. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res. 2001; 61; 6762-6767.
9. Lucon AM, Pereira MA, Mendonca BB et al. Adrenocortical tumors: results of treatment and study of Weiss's score as a prognostic factor. Rev. Hosp. Clin. Fac. Med. São Paulo 2002; 57; 251-256.
10. Klibanski A, Stephen AE, Greene MF et al. Case records of the Massachusetts General Hospital. Case 36-2006. A 35-year-old pregnant woman with new hypertension. N. Engl. J. Med. 2006; 355; 2237-2245.
11. Pohlink C, Tannapfe A, Eichfeld U et al. Does tumor heterogeneity limit the use of the Weiss criteria in the evaluation of adrenocortical tumors? J. Endocrinol. Invest. 2004; 27; 565-569.
12. Ambros V. MicroRNA pathways in flies and worms: growth, death, fat stress, and timing. Cell 2003; 113; 673-676.
13. Veronese A, Lupini L, Consiglio J et al. Oncogene role of Mir-483-3p at IGF2/483 locus. Cancer Res. 2010; 70; 3140-3149.
14. Massagué J, Seoane J, Wotton D. Smad transcription factors. Genes Dev. 2005; 19; 2783-2810.
15. Hao J, Zhang S, Zhou Y et al. MicroRNA 483-3p suppresses the expression of DPC4/Smad4 in pancreatic cancer. FEBS Lett. 2011; 585; 207-213.
16. Giordano TJ, Thomas DG, Kuick R et al. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am. J. Pathol. 2003; 162; 521-531.
17. de Fraipont F, El Atifi M, Cherradi N et al. Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. J. Clin. Endocrinol. Metab. 2005; 90; 1819-1829.
18. Dillhoff M, Liu J, Frankel W, Croce C, Bloomston M. MicroRNA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J. Gastrointest. Surg. 2008; 12; 2171-2176.
19. Meyer-Rochow GY, Jackson NE, Conaglen JV et al. MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets. Endocr. Relat. Cancer 2010; 17; 835-846.
20. Soon PS, Gill AJ, Benn DE et al. Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas. Endocr. Relat. Cancer 2009; 16; 573-583.
21. Wilentz RE, Su GH, Dai JL et al. Immunohistochemical labeling for dpc4 mirrors genetic status in pancreatic adenocarcinomas: a new marker of DPC4 inactivation. Am. J. Pathol. 2000; 156; 37-43.
22. Gupta D, Shidham V, Holden J et al. Value of topoisomerase II alpha, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu immunohistochemical expression for the prediction of biologic behavior in adrenocortical neoplasms. Appl. Immunohistochem. Mol. Morph. 2001; 9; 215-221.
23. Nakazumi H, Sasano H, Iino K et al. Expression of cell cycle inhibitor p27 and Ki-67 in human adrenocortical neoplasms. Mod. Pathol. 1998; 11; 1165-1170.
24. Wachenfeld C, Beuschlein F, Zwermann O et al. Discerning malignancy in adrenocortical tumors: are molecular markers useful? Eur. J. Endocrinol. 2001; 145; 335-341.
25. Schmitt A, Saremaslani P, Schmid S et al. IGFII and MIB1 immunohistochemistry is helpful for the differentiation of benign from malignant adrenocortical tumours. Histopathology 2006; 49; 298-307.
26. Lewinsky BS, Grigor KM, Symington T, Neville AM. The clinical and pathologic features of 'non-hormonal' adrenocortical tumors: report of twenty new cases and review of the literature. Cancer 1974; 33; 778-790.
27. Tang CK, Gray GF. Adrenocortical neoplasms. Prognosis and morphology. Urology 1975; 5; 691-695.
28. Icard P, Chapuis Y, Andreassian B, Bernard A, Proye C. Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery. Surgery 1992; 6; 972-980.
29. Sasano H, Suzuki T, Moriya T. Recent advances in surgical pathology of adrenal incidentaloma. Biomed. Pharmacother. 2000; 54; 169-174.
30. Dackiw AP, Lee JE, Gagel RF, Evans DB. Adrenal cortical carcinoma. World J. Surg. 2001; 25; 914-926.
31. Herrera MF, Grant CS, van Heerden JA, Sheedy PF, Ilstrup DM. Incidentally discovered adrenal tumors: an institutional perspective. Surgery 1991; 110; 1014-1021.
32. Giordano TJ. Molecular pathology of adrenal cortical tumors: separating adenomas from carcinomas. Endocr. Pathol. 2006; 17; 355-363.
33. Patterson EE, Holloway AK, Weng J, Fojo T, Kebebew E. MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer 2011; 117; 1630-1639.
34. Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu. Rev. Med. 2009; 60; 167-179.
35. Logié A, Boulle N, Gaston V et al. Autocrine role of IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell line. J. Mol. Endocrinol. 1999; 23; 23-32.
36. Hahn SA, Schutte M, Hoque AT et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996; 271; 350-353.
37. Hahn SA, Hoque AT, Moskaluk CA et al. Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res. 1996; 56; 490-494.
38. Schutte M, Hruban RH, Hedrick L et al. DPC4 gene in various tumor types. Cancer Res. 1996; 56; 2527-2530.